Additional European Equity News

AstraZeneca (AZN LN) - Co. enters into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy, a novel oral irreversible EGFR inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy. AstraZeneca will make an upfront cost of USD 600mln, with additional payments of up to USD 900mln. (AstraZeneca)

BP (BP/ LN) - Q2 Trading Statement: Upstream production is expected to be between 2,170-2,220mboepd (prev. 2,339mboepd Q/Q), due to seasonal maintenance predominantly in the Gulf of America and the effects of disruption in the Middle East. Gas & low carbon energy is expected to be 750-770mboepd (prev. 798mboepd Q/Q). Oil production & operations is expected to be 1,420-1,450mboepd (prev. 1,541mboepd). Net debt to be between USD 22-23bln (prev. USD 25.3bln Q/Q). (BP)

British Land (BLND LN) - Co. CEO says "they have started the year well, with momentum continuing from the end of the last financial year. Both core markets remain strong. Demand continues to outstrip supply across campuses and retail parks, leasing remains ahead of previous passing rents, and forward indicators give us confidence that these favourable market conditions will persist." (British Land)

Watches of Switzerland (WOSG LN) - FY 2026 (GBP): Revenue 1.83bln (exp. 1.78bln), Adj. EBIT 155mln (exp. 148.4mln), Operating Profit 170mln (prev. 150mln Y/Y), affirms its FY27 outlook. CEO: "We have made an encouraging start to the year which underpins our confidence in delivering another year of strong revenue growth." (Watches of Switzerland)